Pharmabiz4h
Lipella Pharma completes dosing for first cohort in phase 2a trial of LP-310 for oral lichen planus
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, announced the completion of dosing for the first ...
Pharmabiz5h
CapeStart introduces MadeAi, a GenAI-enabled platform for life sciences that transforms literature review and other applications
At the ISPOR Europe 2024 Conference, CapeStart, Inc. debuted MadeAi—a generative AI-based platform that dramatically streamlines the synthesis of clinical information—with its first solution, ...
Pharmabiz2h
China NMPA approves Merck’s Welireg to treat adult patients with certain types of von Hippel-Lindau disease-associated tumours
Merck, known as MSD outside of the United States and Canada, announced that the National Medical Products Administration (NMPA) in China has approved Welireg (belzutifan), for the treatment of adult ...
Pharmabiz6h
SOPHiA GENETICS launches MSK-IMPACT powered with SOPHiA DDM at AMP 2024
SOPHiA GENETICS launches MSK-IMPACT powered with SOPHiA DDM at AMP 2024: Boston, Massachusetts Saturday, November 23, 2024, 16:00 Hrs [IST] SOPHiA GENETICS, a cloud-native healthc ...
Pharmabiz8h
Bioretec inks sales and distribution pact to speed-up the commercialization of RemeOs Trauma Screw in US market
Bioretec inks sales and distribution pact to speed-up the commercialization of RemeOs Trauma Screw in US market: Finland Saturday, November 23, 2024, 14:00 Hrs [IST] Bioretec Ltd, ...
Pharmabiz12h
Zenyaku Kogyo receives Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat chronic ITP in children
Zenyaku Kogyo receives Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat chronic ITP in children: Tokyo Saturday, November 23, 2024, 10:00 Hrs [IST] Zenyaku Ko ...
Pharmabiz10h
Leads Biolabs receives US FDA orphan drug designation for anti-PD-L1/4-1BB bispecific antibody, LBL-024 for treatment of neuroendocrine cancer
Leads Biolabs receives US FDA orphan drug designation for anti-PD-L1/4-1BB bispecific antibody, LBL-024 for treatment of neuroendocrine cancer: Nanjing, China Saturday, November 2 ...
Pharmabiz9h
Philips introduces next-generation BlueSeal helium-free MRI system, integrated with AI-enabled Smart Reading
Philips introduces next-generation BlueSeal helium-free MRI system, integrated with AI-enabled Smart Reading: Amsterdam, the Netherlands Saturday, November 23, 2024, 13:00 Hrs [IS ...
Pharmabiz13h
Japan’s MHLW grants expanded indication approval to GSK’s RSV vaccine, Arexvy for adults aged 50-59 at increased risk of severe RSV disease
Japan’s MHLW grants expanded indication approval to GSK’s RSV vaccine, Arexvy for adults aged 50-59 at increased risk of severe RSV disease: London, UK Saturday, November 23, ...
Pharmabiz14h
Expert highlights the critical role of X-ray and PFT machines in improving the diagnosis of COPD
Expert highlights the critical role of X-ray and PFT machines in improving the diagnosis of COPD: Shardul Nautiyal, Mumbai Saturday, November 23, 2024, 08:00 Hrs [IST] As the awar ...
Pharmabiz14h
PCI to integrate pharmacists' database with Healthcare Professional Registry
PCI to integrate pharmacists' database with Healthcare Professional Registry: Gireesh Babu, New Delhi Saturday, November 23, 2024, 08:00 Hrs [IST] The Pharmacy Council of India (P ...
Pharmabiz6h
Zai Lab, Pfizer enter collaboration on novel antibacterial drug Xacduro in mainland China
Zai Lab (Zai Lab) and Pfizer announced a strategic collaboration for the novel antibacterial drug Xacduro (sulbactam-durlobactam) in mainland China. Pfizer’s affiliated companies will be exclusively ...